Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$7.86 USD
-0.14 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.88 +0.02 (0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Solid Biosciences Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -96.02 | -85.98 | -72.19 | -88.29 | -117.22 |
Depreciation/Amortization & Depletion | 0.17 | 2.64 | 4.08 | 3.90 | 2.55 |
Net Change from Assets/Liabilities | -6.34 | -3.69 | -23.04 | 16.16 | 7.76 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.00 | -10.95 | 13.38 | 11.63 | 14.21 |
Net Cash From Operating Activities | -94.18 | -97.98 | -77.76 | -56.60 | -92.71 |
Property & Equipment | -1.52 | -2.42 | -1.28 | -0.90 | -4.39 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 31.52 | 0.00 | 0.00 | 0.00 |
Investments | 11.20 | 30.05 | -89.80 | 7.50 | 28.90 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 9.69 | 59.16 | -91.09 | 6.60 | 24.52 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.97 | 72.57 | 134.92 | 132.49 | 59.98 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 2.08 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.15 | 0.18 | 0.07 | -3.79 | -2.10 |
Net Cash from Financing Activities | 3.12 | 74.83 | 134.99 | 128.70 | 57.88 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -81.37 | 36.01 | -33.87 | 78.70 | -10.32 |
Cash at Beginning of Period | 157.22 | 121.21 | 155.07 | 76.37 | 86.69 |
Cash at End of Period | 75.85 | 157.22 | 121.21 | 155.07 | 76.37 |
Diluted Net EPS | -4.83 | -10.10 | -10.19 | -25.49 | -43.63 |
Fiscal Year End for Solid Biosciences Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -49.38 | -24.30 | -96.02 | -75.68 | -54.70 |
Depreciation/Amortization & Depletion | -0.02 | -0.21 | 0.17 | 1.11 | 1.51 |
Net Change from Assets/Liabilities | -2.12 | -2.19 | -6.34 | -4.48 | -6.33 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.85 | 1.52 | 8.00 | 5.69 | 4.06 |
Net Cash From Operating Activities | -46.66 | -25.19 | -94.18 | -73.36 | -55.46 |
Property & Equipment | -0.44 | -0.15 | -1.52 | -1.43 | -1.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -43.24 | -38.35 | 11.20 | -34.18 | -9.93 |
Other Investing Activities | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -43.67 | -38.49 | 9.69 | -35.61 | -10.97 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 117.43 | 107.24 | 2.97 | 2.54 | 2.54 |
Issuance (Repayment) of Debt | -0.23 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -4.97 | 0.00 | 0.15 | 0.08 | 0.08 |
Net Cash from Financing Activities | 112.24 | 107.24 | 3.12 | 2.62 | 2.62 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 21.92 | 43.56 | -81.37 | -106.35 | -63.82 |
Cash at Beginning of Period | 75.85 | 75.85 | 157.22 | 157.22 | 157.22 |
Cash at End of Period | 97.76 | 119.41 | 75.85 | 50.87 | 93.40 |
Diluted Net EPS | -0.61 | -0.64 | -0.99 | -1.05 | -1.25 |